Pique Therapeutics is a biopharmaceutical company seeking to become the leader in the development of new therapeutic vaccines, focused initially on the treatment of cancer.

Pique's lead product is a first-in-class therapeutic vaccine (PT 107) for the treatment of non-small cell lung cancer. PT 107 has completed Phase 1 clinical trials, was well tolerated, and had a very good safety profile in cancer patients. PT 107 showed a dramatic improvement in median overall survival (11 months) for patients with late-stage non-small cell lung cancer, more than doubling the expected 4 to 6 months survival in these patients. Remarkably, over 30% of the patients survived 4 years or longer.

PT 107 is currently in a two-arm, double-blind Phase 2 trial, to further examine the safety and efficacy of the drug.

Pique is also utilizing its novel therapeutic vaccine technology in additional areas of oncology, with products in pre-clinical stage for pancreatic, colorectal, and head and neck cancers.

The Company was founded on the research of Eckhard R. Podack, M.D., Ph.D., who is Chair of the Department of Immunology and Microbiology at the University of Miami.